Cat Fredenburgh

Australia's five-year major infrastructure pipeline has skyrocketed to $242 billion, according to a report from the government's infrastructure advisor which warns shortages in labour and low construction productivity could put projects at risk. 

Mayne Pharma has secured an extension of the deadline for securing Foreign Investment Review Board approval of its $672 million tie-up with US drug maker Cosette.

A judge has approved a "modest" $8.7 million settlement in a class action against medical device maker Exactech over allegedly defective joint replacements, saying the settlement was fair and reasonable given the limited assets of the company, whose parent has filed for bankruptcy in the US.

A class action is appealing a ruling that found the federal government owes no duty of care to Torres Strait Islanders to protect them from the effects of climate change, with experts predicting the High Court may ultimately decide the issue. 

Ubiquitous child entertainment group The Wiggles has admitted it likely breached consumer laws by selling Emma light-up headbands without warning consumers the dress-up toy contained button batteries, which can be fatal if swallowed. 

Law firm HFW has expanded its global construction practice by snagging a leading construction lawyer and his team to capitalise on Queensland's construction boom.

In a show of the office market's recovery, GPT Group has reportedly sold 750 Collins Street in Melbourne's Docklands to a private buyer for $383 million.

ASIC has filed proceedings against mineral exploration company AVZ Minerals and two of its directors, alleging the company failed to disclose a critical legal dispute, including a forgery claim, relating to a $32 million lithium mine deal.

The government of Western Australia will not move forward with a planned $1.6 billion redevelopment of the Perth Convention and Exhibition Centre but will instead divert most of its $1.6 billion investment to a hospital infrastructure fund.

Cosette plans to appeal a ruling that rejected its bid to terminate an agreement to merge with Mayne Pharma, as the US drug company also refuses to agree to conditions needed to win Foreign Investment Review Board approval for the tie-up.